Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus

ClpC1 is an emerging new target for the treatment of Mycobacterium tuberculosis infections, and several cyclic peptides (ecumicin, cyclomarin A, and lassomycin) are known to act on this target. This study identified another group of peptides, the rufomycins (RUFs), as bactericidal to M. tuberculosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Choules, Mary P., Wolf, Nina M., Lee, Hyun, Anderson, Jeffrey R., Grzelak, Edyta M., Wang, Yuehong, Ma, Rui, Gao, Wei, McAlpine, James B., Jin, Ying-Yu, Cheng, Jinhua, Lee, Hanki, Suh, Joo-Won, Duc, Nguyen Minh, Paik, Seungwha, Choe, Jin Ho, Jo, Eun-Kyeong, Chang, Chulhun L., Lee, Jong Seok, Jaki, Birgit U., Pauli, Guido F., Franzblau, Scott G., Cho, Sanghyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395927/
https://www.ncbi.nlm.nih.gov/pubmed/30602512
http://dx.doi.org/10.1128/AAC.02204-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395927/
https://www.ncbi.nlm.nih.gov/pubmed/30602512
http://dx.doi.org/10.1128/AAC.02204-18

Ejemplares similares